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Background: The oral glucose tolerance test (OGTT) is standardized globally with a uniform
glucose load of 75 g to all adults irrespective of body size. An inverse association between
body height and 2-hour postload plasma glucose (2hPG) has been demonstrated. Our aim
was to evaluate the relationship between body surface area (BSA) and plasma glucose val-
ues during an OGTT.
Methods: An OGTTwas performed on 2659 individuals at increased cardiovascular risk aged
between 45 and 70 years of age, who had not previously been diagnosed with diabetes or
cardiovascular disease. Their BSAwas calculated according to the Mosteller formula. Study
subjects were divided into five BSA levels corresponding to 12.5, 25, 25, 25, and 12.5% of the
total distribution.
Findings: When adjusted for age, sex, waist circumference, alcohol intake, current smok-
ing, and leisure-time physical activity, BSA level showed an inverse linear relationship with
the 2hPG in all categories of glucose tolerance (p for linearity < 0.001). Moreover, the smaller
the adjusted BSA of the study person, the higher the proportion of newly diagnosed type 2
diabetes based on 2hPG in the OGTT.
Interpretation: Body size has a considerable impact on the findings from a standardized
OGTT. Smaller persons are more likely to be diagnosed as glucose intolerant than relatively
larger sized individuals.
Funding: This work was supported by the State Provincial Office of Western Finland, the
Central Satakunta Health Federation of Municipalities, Satakunta Hospital District, and
the Hospital District of Southwest Finland.
Research in context: Evidence before this study. We searched PubMed using the MeSH terms
‘‘glucose tolerance test”, ‘‘body surface area”, ‘‘body height”, ‘‘body size”, ‘‘glucose toler-
ance”, ‘‘insulin resistance”, ‘‘blood glucose” and ‘‘diabetes mellitus” on March 10, 2019
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 7 ( 2 0 1 9 ) 1 0 7 8 7 7without language restrictions. We also used Cited Reference Search in Web of Science for
relevant articles. The oral glucose tolerance test (OGTT) is standardized globally with a uni-
form glucose load of 75 g to all adults irrespective of body size. An inverse association
between body height and 2-hour postload plasma glucose (2hPG) has been demonstrated.
Several studies have shown that 2hPG predicts all-cause mortality better than elevated
fasting glucose. However, body height or body surface area are not usually adjusted in epi-
demiological studies. It is well known that short adult stature is a risk factor for cardiovas-
cular and all-cause mortality.
Added value of this study. This is the first study to assess the relationship of body surface
area and 2hPG in a typical primary care population at increased cardiovascular risk. Body
surface area has a considerable impact on the result of a standardized OGTT. Smaller indi-
viduals are more likely to be diagnosed as glucose intolerant than relatively larger sized
individuals.
Implications of all the available evidence. There is a possibility that the diagnosis of type
2 diabetes made by an OGTT is a false positive result in a relatively small individual, and a
false negative result in a relatively larger individual. Association of 2hPG concentrations
and mortality may be influenced by body size as confounding factor. Given that the OGTT
is a time and effort consuming test both for patients and laboratory personnel, validity of
the OGTT for different body sizes should be reconsidered.
 2019 Elsevier B.V. All rights reserved.1. Introduction
Fifty years ago, the Committee of the Statistics of the Ameri-
can Diabetes Association proposed an estimation of body sur-
face area (BSA) in order to define the appropriate glucose load
to be used during an oral glucose tolerance test (OGTT) [1]. In
1980, the World Health Organization (WHO) recommended
the global standardization of OGTT with a uniform glucose
load of 75 g [2,3]. This recommendation is still valid [4]
although fasting plasma glucose (FPG) and 2-hour postload
plasma glucose (2hPG) cut-off levels for glucose disorders
are somewhat arbitrary and interpopulation differences in
the frequency distribution of plasma glucose (PG) concentra-
tions exist [5]. Observed ethnic differences might be
explained by the different means of height of those popula-
tions, since several studies have demonstrated an inverse
association between body height and 2hPG [6–9]. Moreover,
our previous study [10] showed that adult height is inversely
related to 2hPG, but only up to a body mass index (BMI) of
35 kg/m2.
Given that height is a one-dimensional measure of the
human body, we hypothesized that BSA as a total surface area
of the human body would be better able to take body size into
account when an OGTT is used as a diagnostic method. More-
over, BSA is an absolute measure defined by the area of body
surface and as such, maybe a more relevant variable than BMI
which is a ratio of weight and the square of height. Fig. 1
shows the interplay between height, BMI and BSA. The effect
of height on BSA is more pronounced than that of BMI. The
aim of the present study is to evaluate the relationship
between BSA and plasma glucose concentrations in an OGTT
given to apparently healthy persons, who were at risk for but
not previously diagnosed with type 2 diabetes (T2D) or cardio-
vascular disease (CVD).2. Methods
Study data was collected in a population survey, the Harmon-
ica (Harjavalta Risk Monitoring for Cardiovascular Disease)
project, which was carried out in south-western Finland in
the rural towns of Harjavalta and Kokemäki in 2005–2007.
An invitation to participate in the project, a validated type 2
diabetes risk assessment form (The Finnish Diabetes Risk
Score questionnaire (FINDRISC) [11], available at https://
www.diabetes.fi/english), a cardiovascular risk factor survey
and a measuring tape for waist circumference measurement
were mailed to all residential inhabitants between the ages
of 45–70 years (n = 6013). FINDRISC-score 12 indicates that
estimated 1 in 6 and 15.1 in 3 will develop T2D within
10 years [11]. Participants were asked to complete and return
the risk factor survey to the healthcare centre if they were
willing to participate in the project. Participation and all the
tests included were free of charge. The participation rate
was 74% (4450/6013).
In the risk factor survey, the participants were asked to
report the latest measure of their blood pressure, their use
of antihypertensive medication, any history of gestational
diabetes or hypertension, self-measured waist circumference
at the level of the umbilicus, and family history (parents/sib-
lings) of coronary heart disease, myocardial infarction or
stroke. A FINDRISC score 12 in Harjavalta or, for logistics
reasons 15 in Kokemäki was also regarded as a risk factor.
Of the 4450 respondents, 3072 (69.0%) had at least one risk
factor but no manifested CVD or diabetes. They were invited
to further examination performed by a trained study nurse.
Valid data of OGTTwas available in 2659 study persons.
Blood samples were obtained after at least 12 h of over-
night fasting and PG levels and lipid profiles were determined.
The OGTT was performed by ingestion of a glucose load of
Fig. 1 – Relationship between height, body mass index (BMI)
and body surface area (BSA).
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sured before and 2-h after from capillary whole blood using
the HemoCue Glucose 201+ system (Ängelholm, Sweden).
The results were converted from capillary whole blood to cap-
illary PG values by the analyzer. The WHO 1999 criteria [12]
were used to classify glucose disorders. On the basis of
2hPG alone, the participants were classified into categories
of newly diagnosed type 2 diabetes (T2D), impaired glucose
tolerance (IGT) and normal glucose tolerance if their 2hPG
were 12.2, 8.9–12.1, and <8.9 mmol/l, respectively. On the
basis of FPG alone, participants were classified into categories
of newly diagnosed T2D, impaired fasting glucose (IFG) and
normal fasting glucose, using the thresholds of 7.0, 6.1–6.9
and 6.0 mmol/l, respectively. We combined IGT and IFG as
intermediate hyperglycemia (IH). The ratio of 2hPG and FPG
was used to illustrate the magnitude of the 75 g glucose dose
to elevate PG level in relation to fasting conditions in persons
with different body sizes. Plasma total cholesterol, triglyc-
erides and HDL cholesterol were measured enzymatically
(Olympus AU604). LDL cholesterol was calculated by Friede-
wald’s formula.
Blood pressure was measured by a study nurse using a cal-
ibrated mercury sphygmomanometer. The participants were
at least 5 min in a sitting position, and the mean of two read-
ings taken at intervals of at least 2 min was used. Weight,
height and waist circumference were measured by a study
nurse. BMI was calculated asweight (kg) divided by the square
of height (m2). Waist circumference was measured at the level
midway between the iliac crest and the lowest rib margin.
BSA was calculated according to the Mosteller formula
[weight (kg)  height (cm)/3600]½ [13]. Study subjects were
divided into five BSA levels: I < 1.70 m2, II 1.70–1.87 m2, III
1.88–2.02 m2, IV 2.03–2.22 m2, V > 2.22 m2, corresponding
12.5, 25, 25, 25, and 12.5% of the total distribution.Education years, leisure-time physical activity (LTPA),
smoking status and Alcohol Use Disorders Identification Test
(AUDIT) [14] were assessed at the clinic after the participants
completed self-administrated questionnaires. LTPA was clas-
sified as high if the LTPA was 30 min at a time and per-
formed six or more times a week, as moderate if LTPA
30 min at a time four to five times a week, otherwise the
LTPA was classified as low.
2.1. Ethical approvall
The ethics committee of Satakunta hospital district reviewed
and approved the study protocol and consent forms. All par-
ticipants provided written informed consent for the project
and subsequent medical research.
2.2. Statistical analysis
The descriptive statistics are presented as means with SDs or
as counts with percentages. Statistical significances for the
unadjusted hypothesis of linearity across categories of BSA
were evaluated by using the Cochran-Armitage test for trend,
logistic models, and an analysis of variance with an appropri-
ate contrast. In the case of violation of the assumptions (e.g.
non-normality), a bootstrap-type test was used. The relation-
ship between diabetes and BSAwas modelled using restricted
cubic splines (with 4 knots, placed according to Harrell’s rec-
ommended percentiles) logistic regression model. Regression
analyses were used to identify the relative effects of height
and weight as predictors of FPG and 2hPG using standardized
regression coefficients Beta (b). The Beta value is a measure of
how strongly each predictor variable influences the criterion
(dependent) variable. The beta is measured in units of stan-
dard deviation. Correlation coefficients were calculated by
the Pearson method. The normality of the variables was
tested by using the Shapiro–Wilk W test. A Stata 15.1 (Stata-
Corp LP; College Station, Texas, USA) statistical package was
used for the analysis.
3. Results
The study included 2659 participants at increased cardiovas-
cular risk with a mean age of 58 ± 7 years, 56% were women.
Table 1 shows the characteristics of the participants accord-
ing to five BSA level groups. The two lowest BSA categories
were dominated by women, the two highest by men. Partici-
pants with higher BSAwere more likely to be younger, to have
higher systolic and diastolic blood pressure, higher plasma
glucose and triglyceride levels, and lower HDL cholesterol
and total cholesterol levels. BSA was positively associated
with other anthropometric measures, AUDIT score, use of
statins and antihypertensive medication, but inversely with
LTPA.
The prevalence of impairment in glucose regulation
increased linearly with rising BSA levels. In subjects with nor-
mal glucose tolerance, FPG was positively and the 2hPG/FPG
ratio negatively associated with BSA. In patients with new
onset T2D, the 2hPG/FPG ratio was inversely related to BSA
(Table 2).

















BSA, m2, mean (SD) 1.63 1.79 1.95 2.11 2.35 ..
Women, n (%) 318 (96) 571 (85) 339 (51) 172 (26) 75 (23) <0.001
Age, mean (SD) 59 (7) 59 (7) 58 (7) 58 (7) 57 (7) <0.001
Education years, mean (SD) 10.6 (2.8) 10.5 (2.7) 10.3 (2.7) 10.3 (2.7) 10.3 (2.6) 0.12
Height, cm, mean (SD) 159 (5) 164 (6) 169 (7) 175 (8) 179 (9) <0.001
Weight, kg, mean (SD) 60 (5) 71 (4) 81 (4) 92 (6) 112 (12) <0.001
BMI, kg/m2, mean (SD) 23.9 (2.6) 26.6 (2.8) 28.7 (3.7) 30.5 (4.2) 35.5 (5.9) <0.001
WC, cm, mean (SD) 79 (7) 88 (7) 96 (7) 103 (8) 116 (11) <0.001
FPG, mmol/l 5.38 (1.26) 5.41 (0.77) 5.59 (1.04) 5.75 (1.14) 6.13 (1.68) <0.001
2hPG, mmol/l 7.39 (2.19) 7.23 (1.88) 7.34 (2.17) 7.44 (2.45) 7.99 (2.81) <0.001
TC, mmol/l, mean (SD) 5.50 (0.96) 5.47 (0.97) 5.41 (0.95) 5.30 (0.98) 5.25 (1.03) <0.001
HDL-C, mmol/l, mean (SD) 1.82 (0.46) 1.71 (0.44) 1.53 (0.41) 1.41 (0.39) 1.27 (0.33) <0.001
LDL-C, mmol/l, mean (SD) 3.20 (0.83) 3.21 (0.89) 3.28 (0.87) 3.25 (0.90) 3.25 (0.94) 0.29
Triglycerides, mmol/l, mean (SD) 1.13 (0.64) 1.25 (0.64) 1.36 (0.67) 1.52 (0.83) 1.76 (0.85) <0.001
Blood Pressure, mmHg, mean (SD)
Systolic 139 (19) 139 (19) 140 (18) 142 (18) 144 (20) <0.001
Diastolic 81 (10) 82 (9) 84 (10) 86 (10) 89 (11) <0.001
Current smoker, n (%) 60 (18) 109 (16) 112 (17) 121 (18) 61 (19) 0.47
AUDIT score, mean (SD) 3.1 (4.0) 3.6 (4.1) 4.7 (4.8) 5.7 (5.2) 6.2 (5.5) <0.001
LTPA, n (%) <0.001
Low 41 (13) 72 (11) 110 (17) 140 (22) 105 (34)
Moderate 140 (43) 341 (52) 339 (52) 324 (51) 150 (48)
High 144 (44) 243 (37) 199 (31) 177 (28) 57 (18)
Current medication, n (%)
Statins 31 (9) 65 (10) 84 (13) 109 (16) 46 (14) <0.001
Antihypertensives 69 (21) 178 (26) 211 (32) 277 (42) 168 (52) <0.001
Abbreviations: BSA, body surface area; BMI, body mass index; WC, waist circumference; FPG, fasting plasma glucose; 2hPG, 2-hour plasma
glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AUDIT, Alcohol Use
Disorders Identification Test; LTPA, leisure-time physical activity.

































FPG, mmol/l 5.11 (0.51) 5.18 (0.49) 5.25 (0.46) 5.32 (0.48) 5.31 (0.41) <0.001
2hPG, mmol/l 6.94 (1.49) 6.91 (1.43) 6.92 (1.63) 6.86 (1.70) 7.02 (1.91) 0.95
2hPG/FPG ratio 1.37 (0.30) 1.34 (0.29) 1.32 (0.32) 1.30 (0.33) 1.33 (0.36) 0.018
IH, mean (SD)
FPG 6.23 (0.52) 6.29 (0.44) 6.37 (0.36) 6.34 (0.25) 6.34 (0.39) 0.21
2hPG 8.36 (1.85) 7.95 (1.87) 8.07 (1.97) 7.61 (1.88) 8.16 (1.93) 0.43
2hPG/FPG ratio 1.35 (0.33) 1.27 (0.33) 1.28 (0.33) 1.20 (0.30) 1.29 (0.32) 0.21
T2D, mean (SD)
FPG 7.68 (3.71) 7.08 (1.66) 7.97 (2.22) 7.87 (2.10) 8.51 (2.48) 0.076
2hPG 13.08 (3.63) 12.70 (2.80) 12.71 (3.35) 12.41 (3.47) 12.45 (3.26) 0.48
2hPG/FPG ratio 2.11 (0.74) 2.05 (0.59) 1.84 (0.57) 1.75 (0.53) 1.66 (0.45) <0.001
Abbreviations:NGT, normal glucose tolerance; IH, intermediate hyperglycemia (defined as IFG or IGT); T2D, type 2 diabetes; FPG, fasting plasma
glucose; 2hPG, 2-hour plasma glucose.
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intake, current smoking, and LTPA, the BSA level showed an
inverse linear relationship with the 2hPG and 2hPG/FPG ratioin all categories of glucose tolerance (p for linearity < 0.001).
Among persons with normal glucose tolerance, the 2hPG/
FPG ratio decreased from 1.47 (95% CI: 1.42–1.52) to 1.23
Fig. 2 – Mean 2-hour plasma glucose (2hPG) and 2hPG per fasting plasma glucose (FPG) ratio. By body surface area and glucose
tolerance category. Adjusted for age, smoking status, leisure time physical activity, alcohol intake, waist circumference and
gender. Error bars are for 95% confidence intervals. The dashed line indicates the 2hPG diagnostic cut-off value for type 2
diabetes.
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sponding figures among subjects with newly diagnosed T2D
were 2.08 (95% CI: 1.91–2.24) and 1.51 (95% CI: 1.40–1.62). There
was an interaction between the BSA and 2hPG/FPG ratio
(p < 0.001) but not between BSA and 2hPG (p = 0.70) (Fig. 2).
Fig. 3 shows the adjusted proportion of new T2D diagnoses
based on the OGTT. BSA was inversely related with new T2D
diagnoses (p-value for linearity < 0.001). In univariate regres-
sion analysis, both height and weight showed a positive rela-
tionship with FPG, the effect of weight being more
pronounced. The relationship of weight was positive with
2hPG, whereas height showed an inverse association with
2hPG (Fig. 4).
4. Discussion
This study indicates that the smaller the adjusted BSA of a
population, the higher the proportion of new T2D cases diag-
nosed by 2hPG in an OGTTwill be. Thus, there is a possibility
that the diagnosis of T2D made by an OGTT is a false positive
result in a relatively small individual, and a false negative
result in a relatively larger individual. This might be a major
importance in certain ethnic groups characterized by small
BSA. It is well known that the diagnostic tests, i.e. fasting glu-
cose, OGTT, and glycated haemoglobin (HbA1c), do not detect
diabetes or impairment in glucose regulation in the same
individual [15,16]. This may be partially the consequence of
different body sizes affecting 2hPG in an OGTT.In the present study, increasing levels of BSA were associ-
ated with higher levels of several cardiometabolic risk factors.
However, when adjusted for age, sex, smoking status, leisure
time physical activity, alcohol intake, and waist circumfer-
ence, higher BSA level was inversely associated with 2hPG
and 2hPG/FPG ratio in all categories of glucose tolerance. This
suggests that BSA, when the effect of central adiposity is
removed, partly determines the rate of glucose metabolism.
We used 2hPG/FPG ratio to examine to what degree the 75 g
glucose dose increased PG concentration in relation to fasting
glucose concentrations. Independently of glucose tolerance
category, 2hPG was lower in relation to FPG when BSAwas lar-
ger. This seems to indicate that the uniform 75 g glucose dose
has smaller impact on 2hPG level when body size is larger
even if FPG concentration has been taken into account. More-
over, as a consequence of their smaller body size, womenmay
be more often diagnosed with T2D or impaired glucose toler-
ance than men.
We used 2hPG/FPG ratio to examine to which degree the
75 g glucose dose elevated PG level in relation to fasting con-
ditions. Independently of glucose tolerance category, 2hPG
was lower in relation to FPG when BSA was larger. This
seems to indicate that the uniform 75 g glucose has smaller
impact on 2hPG level when body size is larger even if FPG
concentration has been taken into account. Moreover, as a
consequence of their smaller body size, women may be
more often diagnosed with T2D or impaired glucose toler-
ance than men.
Fig. 4 – Univariate relationships between body size
predictive variables (height and weight) and diagnostic
variables (FPG and 2hPG). The standardized beta coefficients
(b) with 95% confidence intervals.
Fig. 3 – Proportion of newly diagnosed type 2 diabetes (T2D)
based on 2hPG values according to body surface area (BSA).
The curves were derived from a 4-knot restricted cubic
splines logistic regression models. The models were
adjusted for age, sex, smoking status, leisure time physical
activity, alcohol intake, and waist circumference. The grey
area represents a 95% confidence interval.
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human body in which the organs responsible for glucose
absorption, utilisation and production function. It is reason-
able to assume that the larger the framework, the larger the
internal organs and skeletal muscle mass. Indeed, a larger
BSA has been shown to predict higher total liver volume [17]
and higher infrarenal aortic diameter [18]. Moreover, gut glu-
cose half-life shows an inverse relationship with body height
and fat-free mass [19,20]. Recently, left ventricular size and
mass was reported to be proportional to height and even
more to BSA in US professional basketball players [21].
The basal metabolic rate is seldom considered in studies
focusing upon glucose tolerance and glucose metabolism. It
has been estimated that under fasting conditions, glucose
uptake by the brain is 0.43 mmol/min, by skeletal muscle0.12 mmol/min, and by the heart 0.08 mmol/min per 1.73 m2
BSA [22]. This basal energy consumption of the human body
may partly explain our findings that even among subjects
with normal glucose tolerance, adjusted 2hPG level and
2hPG/FPG ratio decreased with increasing body size. This
probably reflects the physiological response of organs in a lar-
ger body to the same 75 g glucose load which is also given to
smaller persons. Stančáková et al. demonstrated that periph-
eral insulin sensitivity is already decreased within the normal
range of FPG and 2hPG both in non-obese and obese individ-
uals [23]. This finding may be explained by differences in the
body sizes of the study subjects.
Although we propose that 2hPG values may be biased by
body size, it is noteworthy that 2hPG predicted all-cause mor-
tality better than elevated fasting glucose in a meta-analyses
performed by Huang et al. [24] In eleven studies included in
the meta-analysis focusing upon individuals with impaired
glucose regulation, body height or BSA were not adjusted.
Our results suggest that higher 2 h glucose concentration dur-
ing 75 g OGTT identifies individuals with on average smaller
body size. Importantly, it is well known that short adult sta-
ture is a risk factor for cardiovascular and all-cause mortality
[25–27]. Thus, it is possible that after controlling for height-
related confounders, such as body height or BSA, 2hPG values
might not be associated with increased risk of mortality.
The major limitation of our study is the cross-sectional
setting. Therefore, it is not possible to define causal relation-
ships between body size and its inverse effect on 2hPG con-
centrations. However, the study participants represent a
typical primary care population in which an OGTT is fre-
quently used as a screening tool to detect defects in glucose
regulation. It is well known that the reproducibility of an
OGTT is rather poor in asymptomatic individuals. Assigning
the study participants into five groups of BSA makes our
results comparable to other populations based on the fact
that BSA is normally distributed in the general population.
However, results may not be directly generalizable to popula-
tions with different ethnic background. Further, part of the
data was gathered by self-evaluation forms in which compli-
ance and correct responses are not possible to verify.
In conclusion, body size has a considerable impact on the
result of a standardized OGTT. Smaller individuals are more
likely to be diagnosed as glucose intolerant than relatively lar-
ger sized individuals, despite the elevated metabolic risk seen
in larger individuals. Given that OGTT is a time and effort con-
suming test both for patients and laboratory personnel, the
medical community might abandon OGTTs and use FPG
and/or HbA1c as diagnostic tests for glucose disorders. The
alternatives, adjusting the glucose dose to the height or BSA
of a person as recommended fifty years ago [1] or using differ-
ent cut-off values for 2hPG for individuals with different body
sizes, are too cumbersome for clinical practice.5. Contributors
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